Annexon Biosciences has closed a $75 million Series C round of financing, which will be used to develop multiple product candidates, including an antigen-binding fragment candidate for use in ophthalmic settings, the company announced in a press release.
Led by Bain Capital Life Sciences, the financing included participation from Surveyor Capital and Adage Capital Partners, as well as existing investors NEA, Blackstone Life Sciences, Novartis Venture Fund and Satter Investment Management.
“We have made great strides in building a portfolio of product candidates across multiple indications
Uncategorized